Paresh Vyas, MRCP FRCP FRCPath, is a Professor of Haematology at Oxford University. He studied medicine at Cambridge then Oxford. After completing his medical and haematology training in London. He did his PhD with Professor Higgs and Professor Sir Weatherall at the MRC Molecular Haematology Unit, Oxford and did a three years doing a post-doctoral fellowship with Professor Orkin at Harvard University. He is a research active Consultant Haematologist with a clinical practice in myeloid disorders (MDS, AML and MPD) and allogeneic stem cell transplant in Oxford and the MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford. His research focuses on molecular and cellular biology of AML and MDS with specific interest in purification and therapeutic targeting of myeloid preleukaemic and leukaemic stem cells. He studies single cell biology in both normal and leukaemic haemopoiesis.
He is on the UK AML and MDS clinical trial groups. He is co-Lead of the Oxford BRC Haematology Theme, is on the Board of NHSBT, vice-chair of the MRC Clinical Training Panel, Translational Lead for the UK Therapy Acceleration Program. He works with Celgene on the IDH inhibitor program and is global lead for the AML-005 study.